ArticleDiabetology & metabolic syndrome2025
Metabolic score for visceral fat as a superior predictor of frailty in overweight and obese adults: a cross-sectional NHANES analysis (2007-2020).
Article in Diabetology & metabolic syndrome, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe metabolic score for visceral fat (METS-VF) integrates metabolic and anthropometric indices to assess visceral fat burden; however, its relationship with frailty remains underexplored. This study aimed to assess the relationship between the METS-VF and frailty in overweight and obese adults.
methodsWe analyzed data from 6598 overweight/obese individuals (representing 38.8 million U.S. adults) from the 2007-2020 National Health and Nutrition Examination Survey (NHANES). Frailty was determined via a 49-item frailty index. METS-VF was estimated on the basis of insulin resistance, lipid profile, waist-to-height ratio, age, and sex. Associations were evaluated via multivariate logistic regression, restricted cubic splines, and subgroup analyses. Receiver operating characteristic (ROC) curves and decision curve analysis (DCA) were used to compare the predictive performance of the METS-VF with that of the metabolic score for insulin resistance (METS-IR), waist circumference (WC), and body mass index (BMI) for frailty.
resultsThe prevalence of frailty was 13.1%. Each unit increase in the METS-VF was associated with more than a fivefold greater odds of frailty (adjusted odds ratio (OR) = 4.95; 95% CI: 3.35-7.32; P < 0.001). Compared with those in the lowest quartile, participants in Q4 had 3.39-fold greater odds of frailty (95% CI: 2.29-5.01; P < 0.001; P for trend < 0.001). ROC analysis revealed that the METS-VF had superior predictive performance for frailty (AUC = 0.685) compared with the METS-IR, WC, and BMI. DCA further indicated that METS-VF provided greater net clinical benefit across the threshold probability range of 0.15-0.35.
conclusionThe METS-VF was strongly associated with frailty in overweight/obese adults and was superior to the METS-IR, WC, and BMI in predicting frailty. These findings suggest that METS-VF may be useful for the early identification of high-risk populations, although causal inference cannot be made owing to the cross-sectional design.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.